Key Highlights
- Synchron’s equity stake in ACQUANDAS enhances its BCI technology and supply chain.
- Tom Oxley and Riki Banerjee to join ACQUANDAS Governance, bolstering collaboration.
- ACQUANDAS’ advanced fabrication technology pivotal for expanding Synchron’s medical device offerings.
Source: Business Wire
Notable Quotes
- “This investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces,” – Tom Oxley, CEO & Founder at Synchron
- “I am thrilled to welcome Synchron on board as an investor… This major investment will… play a pivotal role in expanding our facilities and capabilities,” – Dr. Rodrigo Lima de Miranda, CEO & Founder at ACQUANDAS
SoH's Take
The acquisition of an equity stake in ACQUANDAS by Synchron represents a strategic move to fortify its position in the brain-computer interface (BCI) sector. This collaboration is set to accelerate the development and deployment of innovative neurotechnology solutions aimed at restoring functionality for patients with severe motor impairments. The inclusion of Synchron’s leadership in ACQUANDAS’ governance underscores a deep commitment to mutual growth and the advancement of healthcare technology. ACQUANDAS’ expertise in manufacturing high-precision components, particularly its advancements in shape-memory metallic components, offers Synchron a competitive edge in the development of implantable medical devices. This partnership not only signifies a robust enhancement of Synchron’s product offerings but also marks a significant leap forward in the broader application of endovascular neurotechnology for therapeutic purposes.
